Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
复制标题
DOI：
10.1200/jco.2005.02.7102
复制
发表时间：
2007-03-01
影响因子：
45.3
通讯作者：
Jakesz, Raimund
中科院分区：
文献类型：
--
作者：
Gnant, Michael F. X.;Mlineritsch, Brigitte;Jakesz, Raimund
目的乳腺癌的辅助治疗可能与骨密度(BMD)降低有关，这可能导致骨骼疾病。这项研究探讨了唑来膦酸能否预防绝经前患者内分泌辅助治疗所导致的骨丢失。患者与方法本研究是一项随机、开放的III期四臂试验，比较了他莫昔芬(20 mg/d口服)+/-唑来膦酸(每6个月4 mg静脉注射)与阿那曲唑(1 mg/d口服)+/-唑来硝酸治疗3年的激素反应性乳腺癌绝经前妇女的疗效。在三个试验中心的BMD子方案中，患者在0、6、12、24和36个月进行了一系列的BMD测量。未使用唑来膦酸的内分泌治疗组与对照组比较，差异有统计学意义(P
PurposeAdjuvant therapy for breast cancer can be associated with decreased bone mineral density (BMD) that may lead to skeletal morbidity. This study examined whether zoledronic acid can prevent bone loss associated with adjuvant endocrine therapy in premenopausal patients.Patients and MethodsThis study is a randomized, open-label, phase III, four-arm trial comparing tamoxifen (20 mg/d orally) and goserelin (3.6 mg every 28 days subcutaneously) +/- zoledronic acid (4 mg intravenously every 6 months) versus anastrozole (1 mg/d orally) and goserelin +/- zoledronic acid for 3 years in premenopausal women with hormone-responsive breast cancer. In a BMD subprotocol at three trial centers, patients underwent serial BMD measurements at 0, 6, 12, 24, and 36 months.ResultsFour hundred one patients were included in the BMD subprotocol. Endocrine treatment without zoledronic acid led to significant (P